v3.25.4
Condensed Consolidated Balance Sheets - USD ($)
Jan. 31, 2026
Jul. 31, 2025
CURRENT ASSETS:    
Cash and cash equivalents $ 29,903,628 $ 10,493,808
Short-term investments 7,372,473
Amounts receivable and prepaid expenses 2,275,256 2,060,295
Total current assets 32,178,884 19,926,576
NON-CURRENT ASSETS:    
Equity investment in BC Therapeutics 582,455 524,278
Intangible assets, net 176,889 184,525
Property and equipment, net 251,141 296,819
Long term prepaid expenses 405,085 717,508
Total non-current assets 1,415,570 1,723,130
Total assets 33,594,454 21,649,706
CURRENT LIABILITIES:    
Trade payables 1,879,647 3,283,703
Accrued expenses and other payables 1,305,903 694,285
Total current liabilities 3,185,550 3,977,988
NON-CURRENT LIABILITIES:    
Warrant liability 195,096 337,672
Total non-current liabilities 195,096 337,672
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY:    
Share Capital of no par value – Authorized: unlimited at January 31, 2026 and July 31, 2025; Issued and outstanding: 7,250,487 shares at January 31, 2026 and 1,883,906 July 31, 2025, respectively 117,117,225 101,739,923
Share-based payment reserved 10,896,682 10,316,140
Warrant reserve 30,216,165 17,719,026
Accumulated other comprehensive loss (138,684) (138,684)
Non-controlling interest (702,631) (546,795)
Accumulated deficit (127,174,949) (111,755,564)
Total shareholders’ equity 30,213,808 17,334,046
Total liabilities and shareholders’ equity $ 33,594,454 $ 21,649,706